COVID-19

COVID-19

The analysis revealed higher prevalence rates in the COVID-19 cohort for Antithrombotic drugs (ATC II: B01), Anti-goutosis drugs (ATC II: M04), and drugs used in cardiac therapy (ATC II: C01). Conversely, the prevalence of drugs acting on the Renin-Angiotensin System (RAS), as well as for other antihypertensive drugs, did not show a statistically significant difference between COVID-19 positive patients and the general reference population.

Drug-utilisation Profiles and COVID-19: Retrospective Cohort Study in Italy